Dr. Vinay Prasad is out at the Food and Drug Administration for the second and hopefully last time within the past 12 months.
New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history -- Data expand ...
Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial. The REACH-DMD study (NCT04587908) showed no significant ...
"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," ...
Taking advantage of investor interest in its Duchenne muscular dystrophy drug, Capricor Therapeutics secured an upsized US$150m late on Thursday from an overnight stock sale. Following an earlier wall ...
"As we prepare to commence the Phase1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, we're excited to present new preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results